With no up­front pay­ment or mile­stones on the line, Nkar­ta and CRISPR join forces on CAR-NK search

Most deals in biotech come with hefty up­front pay­ments at­tached, and the promise of big biobucks if a pro­gram works out. Not this one.

Nkar­ta has struck what CEO Paul Hast­ings calls a “re­al col­lab­o­ra­tion” with CRISPR Ther­a­peu­tics to co-de­vel­op and com­mer­cial­ize two CAR-NK ther­a­pies, in ad­di­tion to an NK+T pro­gram. The duo will split all R&D costs — and any world­wide prof­its — 50/50, Hast­ings said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER